Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
30 May 2024 - 6:01AM
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”)
(NASDAQ: FATE), a clinical-stage biopharmaceutical company
dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune diseases, today announced that
the Company will present at the 2024 Jefferies Global Healthcare
Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York,
New York.
A live webcast, if recorded, of each presentation can be
accessed under “Events & Presentations” in the Investors
section of the Company’s website at www.fatetherapeutics.com. The
archived webcast will be available on the Company’s website shortly
after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical
company dedicated to bringing a first-in-class pipeline of induced
pluripotent stem cell (iPSC)-derived cellular immunotherapies to
patients with cancer and autoimmune diseases. Using its proprietary
iPSC product platform, the Company has established a leadership
position in creating multiplexed-engineered master iPSC lines and
in the manufacture and clinical development of off-the-shelf,
iPSC-derived cell products. The Company’s pipeline includes
iPSC-derived natural killer (NK) cell and T-cell product
candidates, which are selectively designed, incorporate novel
synthetic controls of cell function, and are intended to deliver
multiple therapeutic mechanisms to patients. Fate
Therapeutics is headquartered in San Diego, CA. For
more information, please visit www.fatetherapeutics.com.
Contact:Christina TartagliaPrecision
AQ212.362.1200christina.tartaglia@precisionaq.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From May 2024 to Jun 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Jun 2023 to Jun 2024